| |  Online-Ressource |
|---|
| Verfasst von: | Gaiser, Maria [VerfasserIn]  |
|---|
| | Weis, Cleo-Aron Thias [VerfasserIn] |
|---|
| | Gaiser, Timo [VerfasserIn] |
|---|
| | Buder-Bakhaya, Kristina [VerfasserIn] |
|---|
| | Herpel, Esther [VerfasserIn] |
|---|
| | Warth, Arne [VerfasserIn] |
|---|
| Titel: | Merkel cell carcinoma expresses the immunoregulatory ligand CD200 and induces immunosuppressive macrophages and regulatory T cells |
|---|
| Verf.angabe: | Maria Rita Gaiser, Cleo-Aron Weis, Timo Gaiser, Hong Jiang, Kristina Buder-Bakhaya, Esther Herpel, Arne Warth, Ying Xiao, Lingling Miao and Isaac Brownell |
|---|
| E-Jahr: | 2018 |
|---|
| Jahr: | 08 Feb 2018 |
|---|
| Umfang: | 6 S. |
|---|
| Fussnoten: | Gesehen am 08.08.2019 |
|---|
| Titel Quelle: | Enthalten in: OncoImmunology |
|---|
| Ort Quelle: | Abingdon : Taylor & Franics, 2012 |
|---|
| Jahr Quelle: | 2018 |
|---|
| Band/Heft Quelle: | 7(2018,5) Artikel-Nummer e1426517, 6 Seiten |
|---|
| ISSN Quelle: | 2162-402X |
|---|
| Abstract: | Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer that responds to PD-1/PD-L1 immune checkpoint inhibitors. CD200 is another checkpoint modulator whose receptor is found on tumor-promoting myeloid cells, including M2 macrophages. We found high CD200 mRNA expression in MCC tumors, and CD200 immunostaining was demonstrated on 95.5% of MCC tumors. CD200R-expressing myeloid cells were present in the MCC tumor microenvironment. MCC-associated macrophages had a higher average CD163:CD68 staining ratio (2.67) than controls (1.13), indicating an immunosuppressive M2 phenotype. Accordingly, MCC tumors contained increased densities of FOXP3+ regulatory T-cells. Intravenous administration of blocking anti-CD200 antibody to MCC xenograft mice revealed specific targeting of drug to tumor. In conclusion, MCC are highly CD200 positive and associated with immunosuppressive M2 macrophages and regulatory T-cells. As anti-CD200 antibody effectively targets CD200 on MCC tumor cells in vivo, this treatment may provide a novel immunotherapy for MCC independent of PD-1/PD-L1 blockade. |
|---|
| DOI: | doi:10.1080/2162402X.2018.1426517 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1080/2162402X.2018.1426517 |
|---|
| | DOI: https://doi.org/10.1080/2162402X.2018.1426517 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | CD200 |
|---|
| | immune checkpoint inhibitor |
|---|
| | M2 macrophage |
|---|
| | Merkel cell carcinoma |
|---|
| | regulatory T cell |
|---|
| K10plus-PPN: | 1671035186 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Merkel cell carcinoma expresses the immunoregulatory ligand CD200 and induces immunosuppressive macrophages and regulatory T cells / Gaiser, Maria [VerfasserIn]; 08 Feb 2018 (Online-Ressource)
